This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/3/2026
Good morning, ladies and gentlemen, and welcome to the Strada Critical Medical Fiscal Third Quarter 2026 Earnings Release Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this call is being recorded. I would now like to turn the conference call over to Matt Schneider, CFO of Clinical Services and Vice President of Finance and Investor Relations. Matt, you may begin.
Thank you for standing by and welcome to Strata's conference call and webcast for the quarter-ended September 30th, 2026. We appreciate everyone joining us today. Before we get started, I would like to remind you of the company's forward-looking statement in Safe Harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC. For a more detailed discussion of the risk factors, that could cause these differences. Any forward-looking statements provided during this conference call are made only as of the date of this call. As stated in our SEC filings, Strata disclaims any intent or obligation to update or revise these forward-looking statements, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly historical, comparable, consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release investor presentation and our form 10Q and 10K filings are available on the investor relations section of our website at ir.stratochritical.com. These non-GAAP measures should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa Tomkiel. I'll now turn the call over to Will.
Thank you, Matt, and good morning, everyone. Our strong third quarter results speak for themselves. Q3 was not only ahead of our guidance, but also showed Ostrata's capability to generate significant cash flow with much higher conversions. As more customers turn to our integrated transplant offering for more of their cases, we are demonstrating continued market share gains and clinical services. This helped to drive clinical segment revenue growth of more than 20% sequentially versus Q2 2026. As Melissa will discuss in more detail, our go-to-market is all about creating alignment with our customers' objectives, becoming that trusted long-term partner in a space that's becoming far too complex to go it alone. We saw yet another quarter of sequential margin improvement, driven in large part by achieving our 2027 logistics gross margin target well ahead of plan. Logistics revenue came in towards the high end of our guidance framework, despite both a larger than expected seasonal industry decline during Q3 and a reduction in industry trip distances. We're pleased that following our significant growth and the completion of three acquisitions during Q2, we still saw a reduction in our adjusted SG&A base quarter over quarter. Most importantly, this quarter put a spotlight on the scalability and cash generation potential of our business model with a record 8.6 million of free cash flow in Q3. We're also pleased to report that we're pacing ahead of the medium term goals we sent out at our investor day last November. Looking ahead to 2027, We believe we're on track to achieve our target high-teens organic adjusted EBITDA growth and 30% plus total adjusted EBITDA growth, including acquisitions as well. On the M&A front, we're well ahead of plan for 2026, closing on over $6 million of expected annualized adjusted EBITDA at our targeted mid-single-digit valuation multiple. We have a strong pipeline to deploy additional capital at our target valuations with a focus on opportunities that will further strengthen our strategic position while enhancing our margin and free cash flow conversion profile. Given Strata's improved cash generation, coupled with the receipt of our first passenger sale earn-out, we ended the quarter with roughly $42 million of cash in short-term investments. and that's before our anticipated receipt of an additional $27 million of passenger sale consideration early next year. As such, we are now in a position both to accelerate beyond our target pace of acquisitions as well as opportunistically return cash to shareholders. To that end, today we announced a $20 million share repurchase authorization, allowing us to take advantage of what we see as an attractive valuation for our own stock. In closing, let's bring things back to basics. The underlying driver of our financial performance is simple. Better service, architected for efficiency, and delivered in partnership with our customers to prioritize their individual preferences and our shared goal to save more lives. With that, I'll turn the call over to Melissa.
You're reading a preview of the SRTA Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing